Neuberger Berman Group
ONCT

Neuberger Berman Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Neuberger Berman Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-239
Closed -$513K – 1721
2018
Q2 		$513K Buy
+239
New +$606K ﹤0.01% 1390

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Neuberger Berman Group's ONCT Position: Q3 2018 in Review

Neuberger Berman Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 239 shares — an estimated $513K sold.

Neuberger Berman Group first reported a position in ONCT in Q2 2018 and held it in 1 quarter. The position peaked at $513K in Q2 2018. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

  • Neuberger Berman Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 239 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $513K.
  • Neuberger Berman Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Neuberger Berman Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $513K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Neuberger Berman Group's 13F filing for Q3 2018, filed 13 Nov 2018.